Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
0.3%
-9.54
-47.35
—
—
-0.2%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
— months this scheme and its benchmark share.
Growth of ₹100 since launch
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
398
2.6%
6.9%
9.8%
0%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
UTI - FIIF Sr-2 Quarterly Interval Plan IV
·
Concentration
Number of stocks
0
Top 5 stocks
—
Top 10 stocks
—
Top 20 stocks
—
Lines in the filing
0
Largest holding
—
Largest sector
— —
Effective stocks
—
Sectors held
0
Cash
0.00%
Effective stocks is what the concentration works out to: a fund holding
0 names but most of its money in a few
behaves like a fund of —. Cash includes repo and TREPS, which
every fund parks money in overnight.
UTI - FIIF Sr-2 Quarterly Interval Plan IV
· · holdings
UTI - FIIF Sr-2 Quarterly Interval Plan IV
· · where the money sits
A ₹10,000 monthly SIP over five years
Invested
Value
Gain
XIRR
₹600,000
₹661,327
₹61,327
3.85%
XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has
been invested for a different length of time.
Not investment advice. InvestVerdict is not a SEBI-registered Investment Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 26 Sep 2026.
